Drug Trial Radar · NCT04225156
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Jun 2, 2020
Primary completion
Mar 11, 2026
Study completion Mar 11, 2026
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
Conditions
- Primary Immune Thrombocytopenia
Interventions
efgartigimodBiological
Intravenous infusion of efgartigimod
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Adverse EventsTime frame: Up to 60 weeks
- Frequency and severity of vital signsTime frame: Up to 60 weeks
- Frequency and severity of laboratory assessmentsTime frame: Up to 60 weeks
Locations
87 sites in 18 countries. Site status is shown where the registry gives one.
Investigator Site 0010045
Washington D.C., District of Columbia
Investigator Site 0010037
Ocala, Florida
Investigator Site 0010042
Iowa City, Iowa
Investigator Site 0010040
Columbus, Ohio
Investigator Site 0430002
Vienna, Austria
Investigator Site 0430003
Vienna, Austria
Investigator Site 0320012
Brasschaat, Belgium
Investigator Site 0320011
Bruges, Belgium
Investigator Site 0320014
Turnhout, Belgium
Investigator Site 0320002
Yvoir, Belgium
Investigator Site 3590001
Pleven, Bulgaria
Investigator Site 3590002
Sofia, Bulgaria
Investigator Site 4200001
Brno, Czechia
Investigator Site 4200008
Olomouc, Czechia
Investigator Site 4200006
Ostrava, Czechia
Investigator Site 4200007
Prague, Czechia
Investigator Site 0330009
Créteil, France
Investigator Site 0330018
Montpellier, France
Investigator Site 0330016
Périgueux, France
Investigator Site 0330008
Pessac, France
Investigator site 9950007
Tbilisi, Georgia
Investigator site 9950008
Tbilisi, Georgia
Investigator site 9950009
Tbilisi, Georgia
Investigator site 9950011
Tbilisi, Georgia
Investigator site 9950012
Tbilisi, Georgia
Investigator Site 0490010
Düsseldorf, Germany
Investigator Site 0490008
Essen, Germany
Investigator Site 0360004
Budapest, Hungary
Investigator Site 0360006
Debrecen, Hungary
Investigator Site 0360015
Győr, Hungary
Investigator Site 0360010
Nyíregyháza, Hungary
Investigator Site 0360014
Szombathely, Hungary
Investigator Site 0390014
Milan, Italy
Investigator Site 0390020
Monza, Italy
Investigator Site 0390015
Novara, Italy
Investigator Site 0390010
Ravenna, Italy
Investigator Site 0390011
Reggio Calabria, Italy
Investigator Site 0390018
Reggio Emilia, Italy
Investigator Site 0390019
Rimini, Italy
Investigator Site 0390009
Siena, Italy
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.